TFRC and neoplasm: In conclusion, the evidence reported in this work strongly suggests that the The-0504 ferritin-based nanocarrier is actually capable of low toxicity and high efficacy CD71-targeting, and it is a versatile platform to entrap and selectively redirect wide-spectrum anti-tumor agents that would be too toxic to be used in their naked form in the clinic.